We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug & Device Products
FDAnews Books Library
Events
Form 483s Database
Publications
Webinar Training Pass
eCFR and Guidances
Books
Clinical Products
Advertising
White Papers
Contact Us
About Us
COVID-19
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Zachary L. Stamm
Zachary L. Stamm
Products
PRODUCTS
Global Treat Srl
Zachary L. Stamm
Price:
$117.00
View
Tolmar, Inc.
Michael A. Charles
and
Zachary L. Stamm
Price:
$117.00
View
Tolmar, Inc.
Zachary L. Stamm
Price:
$117.00
View
Lyocontract GmbH
Zachary L. Stamm
Price:
$117.00
View
Ionetix Corp.
Zachary L. Stamm
Price:
$117.00
View
Prescription Alternatives, Inc.
Zachary L. Stamm
Price:
$117.00
View
Prescription Alternatives, Inc.
Zachary L. Stamm
Price:
$117.00
View
Tolmar Inc.
Zachary L. Stamm
Price:
$117.00
View
Abraxis Bioscience LLC
Jamie L. Dion
and
Zachary L. Stamm
Price:
$117.00
View
Lincare Inc.
Zachary L. Stamm
Price:
$117.00
View
View All Products by Zachary L. Stamm
Upcoming Events
28
Jun
Effective Root Cause Analysis and CAPA Investigations for the Life Sciences
13
Jul
FDA Ad and Promo Enforcement Trends: Past, Present and Future
28
Jul
EU-MDR’s Growing Pains: Are You Current with the Latest Developments?
28
Jul
Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does
02
Aug
Medical Device Cybersecurity: Understand the Latest Developments
03
Aug
Pharmaceutical Process Validation: Best Practices for Success
Featured Products
FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485
Selecting and Implementing Electronic Document Management Systems in the EU
Featured Stories
Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared
FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial
FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators
Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
